Needham & Company maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $13.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8 October 28, 2015 11:02 AM GenMark Diagnostics (GNMK) Tops Q3 EPS by 4cOctober 27, 2015 4:44 PM GenMark Diagnostics Reports Q3 Financial ResultsOctober 27, 2015 4:05 PM Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) ReportOctober 26, 2015 2:16 PM